The University of Southampton
University of Southampton Institutional Repository

Global extent of chloroquine-resistant Plasmodium vivax

Global extent of chloroquine-resistant Plasmodium vivax
Global extent of chloroquine-resistant Plasmodium vivax
I wish to thank Ric Price and colleagues1 for highlighting the under-studied chloroquine resistance in Plasmodium vivax in their systematic review and meta-analysis. However, I would question their study inclusion criteria: the primary outcome was “the risk of recurrent P vivax parasitaemia at day 28” when table 1 lists four studies with follow-up periods of less than 27 days. I would also suggest that it seems a shame that two author-reviewers, independently, did not extract and analyse the studies and data for inclusion, as seems standard practice for good systematic reviews. 2 Lastly, although the paper underlines the extent and importance of chloroquine-resistant P vivax, I am none the wiser on what management I should offer in practice to patients from different areas given the prevalence of resistance.

I declare no competing interests.
1473-3099
Brendish, Nathan J.
1c73d43e-79fb-4c3a-88bc-08207d3c3ba8
Brendish, Nathan J.
1c73d43e-79fb-4c3a-88bc-08207d3c3ba8

Brendish, Nathan J. (2015) Global extent of chloroquine-resistant Plasmodium vivax. The Lancet Infectious Diseases, 15 (6). (doi:10.1016/S1473-3099(15)00017-1). (PMID:26008831)

Record type: Article

Abstract

I wish to thank Ric Price and colleagues1 for highlighting the under-studied chloroquine resistance in Plasmodium vivax in their systematic review and meta-analysis. However, I would question their study inclusion criteria: the primary outcome was “the risk of recurrent P vivax parasitaemia at day 28” when table 1 lists four studies with follow-up periods of less than 27 days. I would also suggest that it seems a shame that two author-reviewers, independently, did not extract and analyse the studies and data for inclusion, as seems standard practice for good systematic reviews. 2 Lastly, although the paper underlines the extent and importance of chloroquine-resistant P vivax, I am none the wiser on what management I should offer in practice to patients from different areas given the prevalence of resistance.

I declare no competing interests.

Text
__tsclient_C_Users_brendn_Documents_Brendish proof TLID.pdf - Other
Download (94kB)

More information

e-pub ahead of print date: 17 May 2015
Published date: 15 June 2015
Organisations: University of Southampton

Identifiers

Local EPrints ID: 380714
URI: http://eprints.soton.ac.uk/id/eprint/380714
ISSN: 1473-3099
PURE UUID: 72fbb6b5-05b5-4494-9678-5911c32e45da

Catalogue record

Date deposited: 03 Sep 2015 13:57
Last modified: 19 Jul 2019 20:35

Export record

Altmetrics

Contributors

Author: Nathan J. Brendish

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×